• Caspase-3/NDUFS1 Axis Drives Trichothecene-Induced Mitochond

  2026-06-22

  This study uncovers how trichothecene mycotoxins induce hepatotoxicity by activating caspase-3, which cleaves the mitochondrial complex I subunit NDUFS1, leading to mitochondrial dysfunction and elevated reactive oxygen species (ROS). The research also identifies a feedback loop involving ER-based ERO1α, providing new mechanistic insight into mycotoxin-driven oxidative stress.

• Redefining MCL-1 Targeting: A-1210477 in Translational Cance

  2026-06-21

  This thought-leadership article explores the unique mechanistic and strategic advantages of the MCL-1 inhibitor A-1210477 for translational cancer researchers. Integrating cutting-edge evidence, including landmark breast cancer studies, it outlines how A-1210477 enables precise apoptosis induction in cancer cells and offers actionable guidance for experimental design, positioning APExBIO’s reagent as an indispensable tool in the evolving landscape of apoptosis-focused oncology.

• Clathrin-Mediated Entry of GCRV: Role of Cytoskeletal Inhibi

  2026-06-20

  Wang et al. (2018) systematically profiled pharmacological inhibitors to delineate the cellular entry pathway of genotype III grass carp reovirus (GCRV104). Their findings establish clathrin- and dynamin-dependent, but actin-independent, endocytosis as the dominant viral entry route, refining mechanistic models for aquatic viral pathogenesis and informing future cytoskeletal disruption studies.

• ATS-9R Enables Targeted CCL2 Silencing to Ameliorate GDM Ins

  2026-06-19

  This study demonstrates that the ATS-9R/siCcl2 complex enables precise, non-viral gene delivery to adipose tissue macrophages, resulting in reduced inflammation and improved insulin sensitivity in gestational diabetes models. The findings highlight the translational potential of ATS-9R-mediated gene silencing for metabolic disease research and intervention.

• Chlorin e6 Photosensitizer: Protocols and Innovations in PDT

  2026-06-19

  Chlorin e6 (Ce6) is redefining photodynamic therapy (PDT) with robust, light-triggered anticancer effects and novel immunogenic mechanisms. This article decodes advanced experimental workflows, troubleshooting, and the latest findings on Ce6-induced pyroptosis, providing actionable guidance for applied cancer research.

• Dovitinib (TKI-258): New Horizons in Translational Oncology

  2026-06-18

  Explore how Dovitinib (TKI-258) advances our understanding of metastatic mechanisms and empowers translational researchers to dissect and disrupt receptor tyrosine kinase-driven oncogenesis. This article integrates mechanistic insights, experimental strategies, and strategic guidance, while contextualizing Dovitinib within the evolving landscape of metastasis research and pre-metastatic niche biology.

• iPSC-Based Models Advance Cystic Fibrosis Drug Testing Preci

  2026-06-18

  The referenced study introduces an induced pluripotent stem cell (iPSC) platform that models diverse CFTR mutations in cystic fibrosis, enabling genotype-specific drug testing in human airway cells. This approach improves the translational relevance of preclinical assays and supports therapeutic development, especially for rare CFTR variants.

• High-Throughput Approaches to Identify MoAs in Antibacterial

  2026-06-17

  This study presents an integrated high-throughput screening and machine learning framework to link antibacterial phenotypes with target mechanisms, exemplified by the identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors. The approach advances the precision of mechanism-of-action (MoA) assignment in antibiotic development, with broader implications for optimizing bacterial cell wall synthesis inhibitor models.

• 5-HT2C/1A Receptor Roles in DOM-Induced Biphasic Responses i

  2026-06-17

  This study dissects the specific contributions of 5-HT2A, 5-HT2C, and 5-HT1A serotonin receptors to the inverted U-shaped dose-response curves for head twitch and locomotor activity induced by the hallucinogen DOM in mice. The findings clarify that multiple serotonergic receptor subtypes distinctly modulate behavioral responses to DOM, revealing mechanistic complexity relevant to both psychopharmacology and modeling of neuropsychiatric disease.

• GW4064 (SKU B1527): Optimizing FXR Activation in Metabolic R

  2026-06-16

  This article explores real-world laboratory challenges in FXR pathway research and demonstrates how GW4064 (SKU B1527) addresses assay reproducibility, sensitivity, and workflow reliability. Drawing on quantitative data and best practices, it guides biomedical researchers in selecting, optimizing, and interpreting FXR activation experiments using GW4064 as a potent, selective non-steroidal FXR agonist.

• Dasatinib Monohydrate in Advanced Assembloid Cancer Models

  2026-06-16

  Dasatinib Monohydrate (BMS-354825) unlocks next-generation tumor–stroma studies by enabling high-fidelity kinase inhibition in assembloid systems. This guide details protocol enhancements, troubleshooting, and translational insights for researchers tackling imatinib resistance and microenvironment-driven drug responses.

• Optimizing DNA Delivery with Polyethylenimine Linear (PEI),

  2026-06-15

  This article delivers a scenario-driven guide for optimizing DNA transfection using Polyethylenimine Linear (PEI), MW 40,000 (SKU K1029). Biomedical researchers will find evidence-backed solutions for reproducibility, efficiency, and cost-effectiveness—especially in HEK-293 and related cell lines. Practical scenarios illustrate how this reagent from APExBIO streamlines transient gene expression, recombinant protein production, and cytotoxicity studies.

• Validated HPLC Method for Quantifying Trelagliptin Succinate

  2026-06-15

  This study presents a robust, validated high-performance liquid chromatography (HPLC) method for the quantitative determination of trelagliptin succinate and its process-related impurities in pharmaceutical formulations. The method's precision, sensitivity, and stability-indicating capability address a key gap in quality control for this long-acting DPP-4 inhibitor, supporting both research and manufacturing contexts.

• Annexin V, Human Recombinant: Structural Precision for Advan

  2026-06-14

  Annexin V, a leading phosphatidylserine binding protein, enables unparalleled accuracy in apoptosis assays. Discover how APExBIO’s recombinant Annexin V empowers cell death research through structural rigor and workflow flexibility.

• Gepotidacin (GSK2140944): Redefining Antibacterial Research

  2026-06-13

  Gepotidacin’s unique inhibition of bacterial DNA gyrase and topoisomerase IV empowers researchers to address multidrug-resistant pathogens where legacy antibiotics fail. This article delivers data-driven workflows, troubleshooting expertise, and protocol optimization to unlock reliable, high-impact results in antibacterial research.

454 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page